AESCH, Switzerland, and NANJING, China, May 27, 2019 - DSM Nutritional Products Ltd Branch Pentapharm and Simcere Pharmaceutical Group today announced the execution of an exclusive collaboration agreement to jointly develop and commercialize Batroxobin Concentrated Liquid Defibrase® in China.
Under the terms of agreement, DSM Pentapharm will be responsible for the application and registration of Batroxobin Concentrated Liquid Defibrase® in China, assisting Simcere in the development of Batroxobin Injection, and supplying Batroxobin Concentrated Liquid Defibrase® exclusively and solely to Simcere. Simcere will be responsible for the development, the application and registration of market authorization, production and commercialization of Batroxobin Injection.
DSM Pentapharm General Manager, Mr. Oliver Helmers said: "Simcere is a leading pharmaceutical innovation company in China with a product line covering a number of therapeutic areas. We are very glad to collaborate with Simcere to expand sales of Batroxobin Injection in China, we can leverage their experience and capability of research and development, marketing and business promotion in the field of cardiovascular and cerebrovascular, to benefit more patients.”
Simcere President, Mr. Honggang Feng said: "we are very pleased that DSM Pentapharm and Simcere could enter into this strategic collaboration agreement. The strategic alliance combines DSM's world-leading research and development capabilities and Simcere's domestic drug development and registration experience, which will bring more high quality medicines to Chinese patients, deliver better services to them, and meet the pressing unmet medical needs."
Specific financial terms of the agreement were not disclosed.
About Batroxobin Concentrated Liquid Defibrase®
Defibrase® is the trademark registered by Pentapharm for its Active Pharmaceutical Ingredient (API) Batroxobin, a serine protease. Batroxobin is a thrombin-like enzyme purified from the snake venom of Bothrops moojeni. In contrast to thrombin, which converts fibrinogen into fibrin by splitting off fibrinopeptides A and B, batroxobin only splits off fibrinopeptide A. Defibrase® has a defibrinogenating effect and is used clinically for the treatment of thrombotic diseases. It also reduces whole blood and plasma viscosity. The main therapeutic indications of Batroxobin final drug (injections) include acute cerebral infarction, ischemia caused by vascular occlusive diseases (such as Thromboangiitis obliterans, deep vein thrombosis, and pulmonary embolism) and peripheral and microcirculation dysfunctions (such as sudden deafness, vibration disease).
About DSM
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about 9 billion. The company is listed on NYSE Euronext.
For more information please visit：www.dsm.com
About DSM Pentapharm
Pentapharm is a 70 years science based Swiss company active in diagnostics reagents and kits and in active pharmaceutical ingredients (APIs) with main focus and expertise in hemostasis and thrombosis. Pentapharm is a leader in snake venom derived products with a unique end to end control of the value chain from snake farming to high quality APIs e.g. Defibrase® (batroxobin) and Reptilase® (haemocoagulase). Pentapharm’s innovation ambition is demonstrated through several partnerships with diagnostics and Pharmaceutical companies, research institutes and key opinion leaders to deliver breakthrough solutions that improve patients’ lives, while been at the forefront of new and future regulations. Pentapharm helped several diagnostics partners shorten time to market and increase the performance of their IVD solutions by creating, developing, testing, and manufacturing superior reagents, kit components and OEM products. Pentapharm was acquired in 2007 by Royal DSM.
For more information please visit：www.pentapharm.com
About Simcere
Simcere is a leading research and development-driven Chinese pharmaceutical company with a “State Key Lab of Translational Medicine and Innovative Drug Development”. By combining in house R&D with partnerships, Simcere focuses its efforts on therapeutic areas of oncology, neurology, inflammation/immunology, cardiovascular and infectious diseases, commits to bringing high quality and more effective therapies to patients. At present, Simcere has built a range of strategic collaborations with multinational pharmaceutical companies and innovative biotech companies on research & development and commercialization of innovative pharmaceuticals.
For more information please visit：www.simcere.com